Published in Arzneimittelforschung on October 01, 1989
Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation (1998) 2.28
Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet (1989) 1.83
Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric? Clin Pharmacol Ther (2009) 1.66
Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education. Pharmacogenomics J (2005) 1.53
Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol (2009) 1.41
Quantification of collateral resistance in acute and chronic experimental coronary occlusion in the dog. Circ Res (1976) 1.40
Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler. Eur J Clin Pharmacol (2013) 1.35
Pharmacokinetics of inhaled anaesthetics in a clinical setting: comparison of desflurane, isoflurane and sevoflurane. Br J Anaesth (2000) 1.33
Comparative cardiovascular actions of verapamil and its major metabolites in the anaesthetised dog. Cardiovasc Res (1978) 1.29
Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother (1992) 1.25
Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother (2009) 1.24
Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther (2008) 1.23
Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics (1999) 1.23
Pharmacokinetics and disposition of carvedilol in humans. J Cardiovasc Pharmacol (1987) 1.22
The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J (2007) 1.21
Pharmacokinetics of inhaled anaesthetics in a clinical setting: description of a novel method based on routine monitoring data. Br J Anaesth (2000) 1.20
Dosing accuracy of commonly used disposable insulin pens. Curr Med Res Opin (2010) 1.20
The relation between initial symptoms and signs and the prognosis of whiplash. Eur Spine J (2001) 1.17
Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol (2007) 1.14
4-quinolones inhibit biotransformation of caffeine. Eur J Clin Pharmacol (1988) 1.14
Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol (1993) 1.12
Clinical pharmacokinetics of sevoflurane. Clin Pharmacokinet (1999) 1.12
Respiratory responses to repeated prolonged exposure to 0.12 ppm ozone. Am J Respir Crit Care Med (1994) 1.08
Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with the hf-capsule. Br J Clin Pharmacol (1990) 1.08
Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers. Clin Pharmacol Ther (2010) 1.06
Pharmacokinetics and metabolism of torasemide in man. Arzneimittelforschung (1988) 1.04
A 3-cM commonly deleted region in 6q21 in leukemias and lymphomas delineated by fluorescence in situ hybridization. Genes Chromosomes Cancer (2000) 1.02
Kinetics of the Fab fragments of digoxin antibodies and of bound digoxin in patients with severe digoxin intoxication. Eur J Clin Pharmacol (1986) 1.01
Structure and activities of hospital drug committees in Germany. Eur J Clin Pharmacol (1997) 0.99
Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells. Transplant Proc (1999) 0.99
Scale-up of adhesive transdermal drug delivery systems. Pharm Res (1997) 0.98
Quinolone inhibition of cytochrome P-450-dependent caffeine metabolism in human liver microsomes. Drug Metab Dispos (1991) 0.98
Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway. Kidney Int (2001) 0.98
Drug utilization review on a surgical intensive care unit. Int J Clin Pharmacol Ther (1994) 0.98
Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Biochem Pharmacol (1992) 0.98
Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid. Int J Clin Pharmacol Ther Toxicol (1989) 0.97
Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics (1996) 0.96
Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. Clin Pharmacokinet (1992) 0.93
Effect of ozone on leukocyte function in exposed human subjects. Environ Res (1978) 0.93
Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. Clin Pharmacol Ther (2010) 0.92
Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His. Neurology (2003) 0.92
Pharmacokinetics of ibuprofen sodium dihydrate and gastrointestinal tolerability of short-term treatment with a novel, rapidly absorbed formulation. Int J Clin Pharmacol Ther (2005) 0.92
In vitro analysis of verapamil-induced immunosuppression: potent inhibition of T cell motility and lymphocytic transmigration through allogeneic endothelial cells. Transplantation (2000) 0.91
Effect of pretreatment with the selective beta 1-adrenoceptor antagonist bisoprolol on the subsequent cardiovascular actions and beta-adrenoceptor subtype specific occupancy of celiprolol in healthy man. Eur J Clin Pharmacol (1993) 0.91
Dermal absorption of permethrin following topical administration. Eur J Clin Pharmacol (2005) 0.90
Comparative clinical effects of hydromorphone and morphine: a meta-analysis. Br J Anaesth (2011) 0.90
Inhibitory effects of the selective thromboxane receptor antagonist BM 13.177 on platelet aggregation, vasoconstriction and sudden death. Biomed Biochim Acta (1984) 0.90
Measurement of theophylline absorption from different regions of the gastro-intestinal tract using a remote controlled drug delivery device. Eur J Clin Pharmacol (1986) 0.90
Deletions in the long arm of chromosome 10 in lymphomas with t(14;18): a pathogenetic role of the tumor supressor genes PTEN/MMAC1 and MXI1? Blood (1998) 0.89
Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol (2000) 0.89
Problems and perspectives of phenotyping for drug-metabolizing enzymes in man. Int J Clin Pharmacol Ther (2000) 0.89
Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers. Eur J Clin Pharmacol (2011) 0.89
Intra-individual variability of caffeine elimination in healthy subjects. Int J Clin Pharmacol Ther Toxicol (1992) 0.88
Argatroban for elective percutaneous coronary intervention: the ARG-E04 multi-center study. Int J Cardiol (2010) 0.88
N-acetyl-p-benzoquinone imine-induced changes in the energy metabolism in hepatocytes. Chem Biol Interact (1990) 0.88
Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. Eur J Clin Pharmacol (1987) 0.88
Absolute bioavailability and bioequivalence of glibenclamide (Semi-Euglucon N). Int J Clin Pharmacol Ther Toxicol (1985) 0.88
Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. Drug Metab Dispos (2005) 0.87
The pharmacokinetic and pharmacodynamic profiles of the thromboxane A-2 receptor blocker BM 13.177. Clin Pharmacol Ther (1986) 0.87
Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharmacol Ther (2001) 0.87
Grapefruit juice increases oral nimodipine bioavailability. Int J Clin Pharmacol Ther (1998) 0.86
Absorption of ipsapirone along the human gastrointestinal tract. Br J Clin Pharmacol (1994) 0.85
Application of interphase fluorescence in situ Hybridization for the detection of the Burkitt translocation t(8;14)(q24;q32) in B-cell lymphomas. Blood (1998) 0.85
Appropriate dosing in patients with impaired renal function on medical wards before and after an educational intervention. Int J Clin Pharmacol Ther (2010) 0.85
Comparison of enzyme kinetic parameters obtained in vitro for reactions mediated by human CYP2C enzymes including major CYP2C9 variants. Curr Drug Metab (2010) 0.85
Metabolism of carvedilol in man. Eur J Drug Metab Pharmacokinet (1992) 0.85
Solid-phase extraction and liquid chromatography of torsemide and metabolites from plasma and urine. J Pharm Sci (1990) 0.85
Feasibility of simultaneous fluorescence immunophenotyping and fluorescence in situ hybridization study for the detection of estrogen receptor expression and deletions of the estrogen receptor gene in breast carcinoma cell lines. Virchows Arch (2000) 0.85
Verapamil and drug metabolism by the cytochrome P450 isoform CYP1A2. Eur J Clin Pharmacol (1992) 0.85
Application of interphase cytogenetics for the detection of t(11;14)(q13;q32) in mantle cell lymphomas. Ann Oncol (1998) 0.84
Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer. Clin Pharmacol Ther (2007) 0.83
Dose-effect and pharmacokinetic-pharmacodynamic relationships of the beta 1-adrenergic receptor blocking properties of various doses of carvedilol in healthy humans. Clin Pharmacol Ther (1994) 0.83
Lacking effect of grapefruit juice on theophylline pharmacokinetics. Int J Clin Pharmacol Ther (1995) 0.83
Single dose pharmacokinetics and effects on platelet function of the thromboxane receptor blocker BM 13.177. Eur J Clin Pharmacol (1986) 0.83
Decrease of caffeine elimination in man during co-administration of 4-quinolones. J Antimicrob Chemother (1987) 0.83
Ex vivo--in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A. Clin Pharmacol Ther (2000) 0.83
Kinetics of subcutaneous versus intravenous epoetin-beta in dogs, rats and mice. Pharmacology (1996) 0.83
Clinical and pharmacological investigations of the new saluretic azosemid. Eur J Clin Pharmacol (1978) 0.83
[Gyrase inhibitors. Central nervous side effects and inhibition of methylxanthine elimination]. Dtsch Med Wochenschr (1990) 0.83
Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator bm 06.022 in healthy volunteers. Thromb Haemost (1991) 0.82
Variation of CYP1A2-dependent caffeine metabolism during menstrual cycle in healthy women. Int J Clin Pharmacol Ther (2000) 0.82
Interaction between quinolones and caffeine. Drugs (1987) 0.82
Detection of 6q deletions in breast carcinoma cell lines by fluorescence in situ hybridization. Hum Genet (1998) 0.82
Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a. Int J Clin Pharmacol Ther (2007) 0.81
[The value of platelet function tests]. Vasa (2003) 0.81
Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects. Br J Clin Pharmacol (2001) 0.81
Gyrase-inhibitors impair caffeine elimination in man. Methods Find Exp Clin Pharmacol (1987) 0.81
Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease. Clin Pharmacokinet (2001) 0.81
Investigation of nifedipine absorption in different regions of the human gastrointestinal (GI) tract after simultaneous administration of 13C- and 12C-nifedipine. Eur J Clin Pharmacol (1996) 0.81
Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. Bone (2002) 0.81